ARVINAS INC. - COMMON STOCK

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

01 5 2025 04:00:24 提供 Nasdaq GlobeNewswire

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

28 4 2025 04:00:00 提供 Nasdaq GlobeNewswire

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

28 4 2025 03:45:37 提供 Nasdaq GlobeNewswire

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 4 2025 07:44:25 提供 Nasdaq GlobeNewswire

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

21 4 2025 04:00:54 提供 Nasdaq GlobeNewswire

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

04 4 2025 04:00:08 提供 Nasdaq GlobeNewswire

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

27 3 2025 04:00:24 提供 Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

11 3 2025 03:45:00 提供 Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

04 3 2025 13:05:09 提供 Nasdaq GlobeNewswire

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

11 2 2025 04:00:04 提供 Nasdaq GlobeNewswire

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

03 2 2025 04:00:49 提供 Nasdaq GlobeNewswire

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

10 1 2025 04:00:19 提供 Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

10 12 2024 06:05:00 提供 Nasdaq GlobeNewswire

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

27 11 2024 04:00:31 提供 Nasdaq GlobeNewswire

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

25 11 2024 14:35:18 提供 Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

04 11 2024 04:00:13 提供 Nasdaq GlobeNewswire

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

30 10 2024 04:00:45 提供 Nasdaq GlobeNewswire

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

22 10 2024 13:05:06 提供 Nasdaq GlobeNewswire

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

21 10 2024 04:00:00 提供 Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

29 8 2024 04:00:48 提供 Nasdaq GlobeNewswire